4.6 Article

Adenine base editing in an adult mouse model of tyrosinaemia

期刊

NATURE BIOMEDICAL ENGINEERING
卷 4, 期 1, 页码 125-130

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-019-0357-8

关键词

-

资金

  1. NCI NIH HHS [F31 CA224800, T32 CA203702, K22 CA181280, R01 CA195787, P30 CA014051] Funding Source: Medline
  2. NHGRI NIH HHS [RM1 HG009490] Funding Source: Medline
  3. NHLBI NIH HHS [DP2 HL137167, UG3 HL147367, P01 HL131471] Funding Source: Medline
  4. NIAID NIH HHS [U01 AI142756] Funding Source: Medline
  5. NIBIB NIH HHS [R01 EB022376] Funding Source: Medline
  6. NIGMS NIH HHS [R35 GM118062, T32 GM095450] Funding Source: Medline

向作者/读者索取更多资源

Intravenous delivery of an adenine base editor and a single-guide RNA for the Fah gene can correct an A>G splice-site mutation in an adult mouse model of tyrosinaemia. In contrast to traditional CRISPR-Cas9 homology-directed repair, base editing can correct point mutations without supplying a DNA-repair template. Here we show in a mouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine base editor (ABE) and a single-guide RNA (sgRNA) can correct an A>G splice-site mutation. ABE treatment partially restored splicing, generated fumarylacetoacetate hydrolase (FAH)-positive hepatocytes in the liver, and rescued weight loss in mice. We also generated FAH(+) hepatocytes in the liver via lipid-nanoparticle-mediated delivery of a chemically modified sgRNA and an mRNA of a codon-optimized base editor that displayed higher base-editing efficiency than the standard ABEs. Our findings suggest that adenine base editing can be used for the correction of genetic diseases in adult animals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据